
CBIO vs GSK
$CBIO vs $GSK head to head: price, market cap, valuation, dividend, free float, relative volume and how actively each trades. The bigger value in the size rows is bolded. Tap either ticker for its live chart, full ownership breakdown and real-time alerts.
CBIO vs GSK: the quick read
- ·GSK is the larger company by market cap ($94.14B vs $524M).
- ·CBIO has been more active on our scanner (73 vs 62 alerts in 30 days).
- ·CBIO has the smaller float (28.9M vs 2.00B), which tends to mean sharper, more volatile moves.
- ·Both are pharmaceutical preparations names, so this is a like-for-like comparison and sector news tends to move them together.
- ·Both stay busy on our scanner, 73 and 62 unusual-volume alerts over 30 days, so neither is the quiet one here.
- ·They are not really peers by size: GSK is more than 179x the market cap of CBIO, so the same dollar of news moves CBIO far harder.
- ·GSK pays a dividend and CBIO does not, which usually means one is being held for income and the other for the move.
- ·GSK is the one in play today, trading about 2.2x its normal volume, which is what puts a name on our scanner in the first place.
Objective differences only. Not investment advice.
Get the best catches in your inbox
Free daily email of the top plays and unusual-volume alerts our scanner flags. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Frequently asked questions
Everything you need to know comparing CBIO and GSK on TheDesperateTrader.
- Is CBIO or GSK the better stock?
- "Better" depends on your goal, and these two are not alike. GSK is the larger company by market cap ($94.14B vs $524M). CBIO has been more active on our scanner (73 vs 62 alerts in 30 days). CBIO has the smaller float (28.9M vs 2.00B), which tends to mean sharper, more volatile moves. Those are the measured differences, not a recommendation, and nothing here is investment advice.
- What is the difference between CBIO and GSK?
- The differences that matter: GSK is roughly 179x the size of the other by market cap ($524M vs $94.14B); they trade at very different share prices ($14.12 vs $46.51); CBIO sits at 29% of its 52-week range against 19% for GSK; only GSK pays a dividend; our scanner flagged CBIO 73 times in the last 30 days against 62 for GSK. Everything above is measured from the latest completed session and SEC filings.
- Which of CBIO and GSK is more active right now?
- Right now CBIO is at about 0.7x its normal volume and GSK is at about 2.2x, so GSK is the one drawing unusual attention today. Relative volume (RVOL) compares a stock's volume to its own recent average, so it reads the same way for a megacap and a microcap and is the quickest way to tell which of two similar names is actually in play.
- Is this comparison data live?
- Prices and % changes are anchored to the latest completed session and split-adjusted, so a reverse split never shows as a fake move. Float is estimated from SEC filings and refreshed as new filings publish.
Trading CBIO or GSK? Get real-time unusual-volume alerts the moment either one moves, free.
No card · 5 premium daysExplore the market
Free, live market tools. No account required to look.